Abstract
Patients diagnosed with non-clear renal cell carcinoma have often been excluded from clinical trials due to the shortage of treatments available, the low incidence of tumours with non-clear histology, and the corresponding diversity of intrinsic molecular features. This approach led to a knowledge gap in finding the optimal treatment for patients diagnosed with non-clear cell renal carcinoma. Cabozantinib, a potent multiple tyrosine kinase receptor inhibitor, has been recently investigated in patients with non-clear cell histologies of renal cell cancer. In this review, we have summarized available data on the use of cabozantinib in non-clear renal cell carcinoma.
Original language | English |
---|---|
Article number | 102921 |
Journal | Critical Reviews in Oncology/Hematology |
Volume | 149 |
Early online date | 3 Mar 2020 |
DOIs | |
Publication status | Published - 31 May 2020 |
Bibliographical note
Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.Keywords
- Anilides/therapeutic use
- Antibodies, Monoclonal/therapeutic use
- Antineoplastic Agents/therapeutic use
- Carcinoma, Renal Cell/drug therapy
- Disease-Free Survival
- Humans
- Kidney Neoplasms/drug therapy
- Protein Kinase Inhibitors
- Pyridines/therapeutic use